Intervention

Datopotamab deruxtecan

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 11 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials11
Recruiting4
Common conditions24
Lead sponsors shown7
Advertisement

Clinical trials

11 shown
PREDICT-RD: ctDNA Surveillance in TNBC With Residual DiseaseNCT07069595 · 2026-02-26
RECRUITING
A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)NCT06822543 · 2025-09-12
RECRUITING
Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain MetastasesNCT05866432 · 2023-07-01
RECRUITING
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerNCT01042379 · 2010-03-01
RECRUITING
Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain MetastasesNCT06676917 · 2025-06-01
WITHDRAWN
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic AlterationsNCT05687266 · 2022-12-29
ACTIVE_NOT_RECRUITING
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung CancerNCT04612751 · 2021-02-02
ACTIVE_NOT_RECRUITING
Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)NCT04526691 · 2020-09-15
ACTIVE_NOT_RECRUITING
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)NCT03944772 · 2019-06-25
ACTIVE_NOT_RECRUITING
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerNCT03742102 · 2018-12-21
ACTIVE_NOT_RECRUITING
Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC PatientsNCT06279728
APPROVED_FOR_MARKETING

Common conditions

Trial status mix

ACTIVE_NOT_RECRUITING5
RECRUITING4
APPROVED_FOR_MARKETING1
WITHDRAWN1

Phase mix

PHASE27
PHASE13
PHASE31
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.